Brief: Cantargia Reports U.S. Regulatory Approval To Start Pancreatic Cancer Phase IIb Trial With Nadunolimab
20/02/2024 15:13
Feb 20 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS US REGULATORY APPROVAL TO START
PANCREATIC
CANCER PHASE IIB TRIAL WITH NADUNOLIMAB
* TRIAL IS PLANNED TO START MID-2024 WITH INITIAL RESULTS
2025
Source text for Eikon: ID:nMFN2yjzhy
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))